News

There have been significant advances in the diagnosis and treatment of indolent SM in recent years, although more research is still necessary.

Midostaurin can be an effective therapy in the management of aggressive systemic mastocytosis.

A new expanded access program (EAP) has been launched for patients with SM, allowing eligible patients to receive bezuclastinib.

A Phase 2 clinical study called Apex is currently evaluating the safety and efficacy of bezuclastinib in patients with advanced SM.

Mast cells in patients with systemic mastocytosis (SM) appear to express increased levels of galectin-3 and galectin-8.

A new review urges researchers to take a closer look at the bone marrow microenvironment when considering future treatment for SM.

A combination of quantitative and laboratory techniques may be used to improve the diagnosis of SM with flow cytometry, a recent study found.

New research highlights the link between clonal mast cell diseases like SM and severe systemic reactions to certain insect stings.

Osteoporosis affects 42% of people with indolent systemic mastocytosis (ISM) and is linked to spine and peripheral fractures.

A clinical trial is currently underway to determine the optimal dosage of a novel cancer drug in patients with ISM.